Tag Archives: immune

Surrogate endpoints for overall survival in lung cancer patients treated with PD-1/PD-L1 blockade

Anti PD-1/PD-L1 antibodies are becoming key therapies in the treatment for advanced non-small-cell lung cancer (NSCLC). Surrogate endpoints for overall survival (OS) such as tumor response and progression-free survival (PFS) are useful to detect drug efficacy earlier,